Table 3.
Multivariate discrete time proportional hazards models of factors associated with time to developing significant fibrosis (APRI ≥ 1.5) in follow-up
| Primary analyses | Secondary analyses | |||
|---|---|---|---|---|
| Adjusted HR | 95% CI | Adjusted HR | 95% CI | |
| Time-updated exposures | ||||
| Virological blip | 0.5 | 0.2, 1.1 | – | – |
| Virological rebound | 2.3 | 1.1, 4.7 | – | – |
| Total log copies HIV RNA | – | – | 1.2 | 1.0, 1.3 |
| CD4 count (per 100 cells/μL) | 1.0 | 0.9, 1.2 | 1.0 | 0.9, 1.1 |
| Time-independent baseline covariates | ||||
| Age (per 10 years) | 1.3 | 0.9, 1.8 | 1.3 | 0.9, 1.8 |
| Sex (female) | 1.2 | 0.6, 2.3 | 1.3 | 0.6, 2.6 |
| Ethnicity (Aboriginal) | 1.0 | 0.4, 2.7 | 0.8 | 0.3, 2.4 |
| Current alcohol abuse | 1.2 | 0.7, 2.1 | 1.2 | 0.7, 2.3 |
| ln (APRI) | 6.3 | 3.1, 12.6 | 5.9 | 2.9, 12.1 |
APRI, aspartate aminotrasferase to platelet ratio; CI, confidence interval; HR, hazard ratio.